Boston Scientific has won approval for its Wavewriter spinal cord stimulator (SCS) systems in non-surgical back pain (NSBP).

The U.S. Food and Drug Administration approval expands the label of the Wavewriter systems to cover the treatment of chronic low back and leg pain in people without prior back surgery. The company announced the approval on Tuesday.

Nevro won FDA approval in non-surgical refractory back pain in early 2022, becoming the first company to enter the space, and Abbott followed up with authorization in NSBP in May.